The group's principle activities include discovering, developing and manufacturing potent, targeted molecular immunotherapies Tarmogens for the treatment of infectious diseases and cancer. The group's products include GI-5005, GI-8000, GI-9000, GI-4000, GI-6207, GI-3000 and GI-10000. The group operates from United States.
Executive Information
Name
Title
Email
Timothy Rodell
Dir., CEO, Pres.
N/A
David Apelian
VP - Clinical Development, Regulatory Affairs, Chief Medical Officer
